Analysis of the Clinical Advancements for <i>BRCA</i>-Related Malignancies Highlights the Lack of Treatment Evidence for <i>BRCA</i>-Positive Male Breast Cancer

Analysis of the Clinical Advancements for <i>BRCA</i>-Related Malignancies Highlights the Lack of Treatment Evidence for <i>BRCA</i>-Positive Male Breast Cancer

Male breast cancer (MBC) is a rare disease that accounts for less than 1% of all breast cancers and male malignancies. Despite recognised clinico-pathological and molecular differences to female breast cancer (FBC), the clinical management of MBC follows established FBC treatment strategies. Loss of...

Full description

Bibliographic Details
Main Authors: Dylan P. McClurg, Gordan Urquhart, Trevor McGoldrick, Subarnarekha Chatterji, Zosia Miedzybrodzka, Valerie Speirs, Beatrix Elsberger
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Cancers
Subjects:
male breast cancer
<i>BRCA</i>
clinical management
PARP inhibitors
Online Access:https://www.mdpi.com/2072-6694/14/13/3175

Similar Items

Similar Items